Condition: Recidivism · Sponsor: The University of Hong Kong
Overall, the investigators hypothesize that participants assigned to the intervention group (Project ReBond) will demonstrate significantly greater improvements across all outcomes compared to the control group. Specifically, the investigators expect positive intervention effects on desistance and TPB outcomes to become evident as participants transition back into the community (i.e., across the at 1-2 months, 6-7 months, and 13-14 months post-release assessment waves), while workshop-specific outcomes will be evident at the end of the workshop. Overall Design The current study employs a two-arm, parallel-group randomized controlled trial (RCT) utilizing a mixed design. The between-subjects factor is the treatment condition (Project ReBond Intervention plus TAU versus TAU Control), and the within-subjects factor is time, with repeated measures assessed across multiple time points over a 13-month tracking period. Intervention Group (Project ReBond + TAU) Participants allocated to the intervention group will receive the multifaceted Project ReBond services alongside standard care (TAU) for up to two years, beginning during their incarceration and continuing post-release. It should be noted that the 13-month research tracking period is shorter than the full two-year service duration; this truncated follow-up is necessary due to anticipated challenges in recruiting the predefined sample size before the project's overall deadline. The TAU is provided by the collaborating non-go…
This description comes directly from the study's public registry record.
Sunny Chow, BSocSc · 85295565912 · suunyccc@hku.hk
Kylie Lui, P.h.D. (Soci) · 8523910 2115 · kcylui@hku.hk
Always discuss trial participation with your own doctor first.
| The University of Hong Kong | Hong Kong, Hong Kong Island, Hong Kong | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07593534